OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
August 15, 2024 12:13 ET
|
OKYO Pharma LTD
LONDON and NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
Doheny Eye Institute Appoints SriniVas Sadda, MD, as the A. Ray Irvine, Jr., MD, Endowed Chair
August 14, 2024 09:00 ET
|
Doheny Eye Institute
PASADENA, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Doheny Eye Institute, one of the nation’s leading vision research institutions, announced that SriniVas Sadda, MD, Director of Artificial...
Clearside Biomedical Announces Second Quarter 2024 Financial Results and Provides Corporate Update
August 12, 2024 16:05 ET
|
Clearside Biomedical, Inc.
- Phase 2b ODYSSEY Trial in Wet AMD Remains on Track with Topline Data Expected in Late Q3 2024 - - ODYSSEY Safety Review Committee Recommends Trial Continue as Planned with no Serious Adverse...
Eclipse Life Sciences Initiates Phase 2 Study for Novel Ophthalmology Steroid Implant for Diabetic Macular Edema (DME)
August 12, 2024 07:45 ET
|
Eclipse Life Sciences
RESEARCH TRIANGLE PARK, N.C., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Eclipse Life Sciences, Inc., a privately held clinical-stage biopharmaceutical company focused on the development of novel therapies...
Clearside Biomedical to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
August 08, 2024 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Age-Related Macular Degeneration (AMD) Market Forecast Report by Disease Type, Product, Distribution Channel, Countries, and Company Analysis: 2024-2032
August 08, 2024 06:55 ET
|
Research and Markets
Dublin, Aug. 08, 2024 (GLOBE NEWSWIRE) -- The "Age-Related Macular Degeneration Market Forecast Report by Disease Type Product Distribution Channel Countries and Company Analysis, 2024-2032" report...
Ocugen Provides Business Update with Second Quarter 2024 Financial Results
August 08, 2024 06:45 ET
|
Ocugen
Conference Call and Webcast Today at 8:30 a.m. ET Actively dosing patients in OCU400 Phase 3 liMeliGhT clinical trialOCU410 preliminary safety and efficacy data expected later this year Expanded...
Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa
August 05, 2024 06:30 ET
|
Ocugen
MALVERN, Pa., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock
August 02, 2024 15:22 ET
|
Ocugen
MALVERN, Pa., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and...
Clearside Biomedical to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024
August 01, 2024 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...